PharmaDrug Inc signs deal with Southwest Research Institute to begin manufacturing potential esophageal cancer and coronavirus treatment Cepharanthine
PharmaDrug signs deal to begin manufacturing potential esophageal cancer and coronavirus treatment Cepharanthine In connection with its recent acquisition of Sairiyo Therapeutics, the company has secured an exclusive license to develop and commercialize a novel oral formulation Cepharanthine is a natural product and has been approved for more than 70 years in Japan for a variety of acute and chronic diseases PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) announced it has reached an agreement with Southwest Research Institute (SwRI) to initiate clinical and non-clinical manufacturing of...
Source: proactiveinvestors.com